Handbook of Dystonia
Botulinum toxin: From molecule to clinic
Publication
, Chapter
Calakos, N
January 1, 2006
Treatment with botulinum toxin has fast become the mainstay for the management of focal dystonias. Its wide utility lies in the fact that, by harnessing the chemical denervation properties of this toxin, one can functionally weaken the endpoint of dystonia irrespective of its etiology. The goal of this chapter is to summarize the molecular and cellular mechanisms of botulinum toxin, highlighting areas in need of further investigation and practical treatment issues in need of optimization. Such an understanding of the principles of botulinum toxin action is paramount to developing the next generation of therapeutic agents.
Duke Scholars
ISBN
9780849376122
Publication Date
January 1, 2006
Start / End Page
343 / 354
Citation
APA
Chicago
ICMJE
MLA
NLM
Calakos, N. (2006). Botulinum toxin: From molecule to clinic. In Handbook of Dystonia (pp. 343–354).
Calakos, N. “Botulinum toxin: From molecule to clinic.” In Handbook of Dystonia, 343–54, 2006.
Calakos N. Botulinum toxin: From molecule to clinic. In: Handbook of Dystonia. 2006. p. 343–54.
Calakos, N. “Botulinum toxin: From molecule to clinic.” Handbook of Dystonia, 2006, pp. 343–54.
Calakos N. Botulinum toxin: From molecule to clinic. Handbook of Dystonia. 2006. p. 343–354.
ISBN
9780849376122
Publication Date
January 1, 2006
Start / End Page
343 / 354